BioArctic’s Leqembi Launches in EU, Targeting Alzheimer’s Disease

BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.

BioArctic AB’s partner Eisai has launched Leqembi in the EU, starting with Austria and Germany, following its approval by the European Commission as the first therapy targeting the underlying cause of Alzheimer’s disease. This launch marks a significant step in addressing the unmet need for treatments that slow the progression of Alzheimer’s, potentially impacting the company’s market position and providing new options for patients and healthcare providers.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

More about BioArctic AB Class B

BioArctic AB is a company operating in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. Its primary product, Leqembi, is a treatment for Alzheimer’s disease, developed in collaboration with Eisai. The company is involved in the commercialization of Leqembi in the Nordic region.

YTD Price Performance: 20.90%

Average Trading Volume: 184,880

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK21.35B

See more data about BIOA.B stock on TipRanks’ Stock Analysis page.